Pfizer Inc (NYSE:PFE) shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot trial, adding pressure as risk appetite stays soft with the S&P 500 trading lower. The move comes as enrollment falls flat and investors recalibrate expectations for the pace of COVID-related product demand.

Tariff Headlines Add Fresh Policy Risk

Pfizer sentiment is also getting tugged by Washington policy risk after a potential 100% tariffs framework surfaced for drugmakers without pricing deals, with an announcement timeline as soon as Thursday.

Pfizer and BioNTech SE – ADR (NASDAQ:BNTX) halted recruitment for a large U.S. trial of their updated COVID-19 vaccine for adults ages 50 to 64 after struggling to enroll enough participants, and the companies said they notified the FDA.

The study targeted 25,000 to 30,000 enrollees, and Pfizer said it will stop monitoring participants for COVID-19 symptoms after April 3 after enrollment had already been closed on March 6.

Trial Halt Clouds COVID Vaccine Visibility

Pfizer is also navigating a shifting public-health backdrop after the CDC paused diagnostic testing for 27 infectious diseases, including respiratory panels for SARS‑CoV‑2 and influenza A and B, in an agency downsizing move.

That policy churn matters for Pfizer because it can complicate how investors handicap near-term COVID vaccine visibility and surveillance-driven demand signals, as paused diagnostic testing becomes part of the narrative.

The broader market is also leaning risk-off Tuesday afternoon, with the S&P 500 down 0.45% and the Nasdaq down 0.7%.

Technical Setup Still Leans Bullish Despite Pullback

The trial pause puts attention back on how quickly COVID vaccine demand is normalizing and what that means for near-term sentiment around Pfizer's vaccine franchise. At $27.05, Pfizer is trading 0.8% below its 20-day simple moving average (SMA), the stock's average price over the last 20 sessions, which suggests the latest pullback is pressuring the short-term trend, while it's trading 3.4% above its 100-day SMA, indicating the intermediate trend still leans constructive.

The moving average convergence divergence (MACD), a trend/momentum measure, is bullish with the MACD at 0.3190 above the 0.2221 signal line, which points to underlying upside momentum even as the stock dips. The golden cross in October (Oct. 10, 2025) keeps the longer-term trend framework tilted positive, since the 50-day SMA remains above the 200-day SMA.

Over the last 12 months, the stock is up 19.80%, a backward-looking gain that shows the longer-term recovery has held despite headline volatility. Pfizer is also sitting closer to its 52-week high of $28.75 (set April 2) than its 52-week low of $20.91, which suggests positioning has improved versus last year's trough.

  • Key Resistance: $27.50 — a level where recent rallies have tended to stall.
  • Key Support: $26.50 — an area where buyers have recently shown up.

Pfizer's Global Scale Keeps Policy Risk In Focus

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion, and it now leans heavily on prescription drugs and vaccines. Key products include the pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis.

Tariff and pricing-policy risk is also creeping back into the Pfizer setup after a Section 232 national-security investigation framework was cited as the basis for potential levies, with exemptions for certain medicines and disease categories still possible.

Pfizer has been listed among major drugmakers that secured three-year reprieves by agreeing to most-favored-nation pricing, but the broader 100% tariff headline can still raise the market's perceived policy beta for the group.

It sells globally, with international markets making up about 40% of total sales, and emerging markets are an important part of that mix.

That scale matters for today's news because changes in COVID vaccine trial strategy can affect how investors think about the durability of Pfizer's vaccine revenue stream and the company's ability to prioritize higher-return programs.

Pfizer’s May 5 Report Could Be The Next Catalyst

Following last quarter’s results, investors are now tracking the path toward the next reporting date on May 5.

  • EPS Estimate: 74 cents (Down from 92 cents YoY)
  • Revenue Estimate: $13.88 Billion (Up from $13.71 Billion YoY)
  • Valuation: P/E of 20.5x (Suggests fair valuation relative to peers)

Analyst Consensus Shows Cautious Upside

Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $29.87. Recent analyst moves include:

  • Guggenheim: Buy (Raises Target to $36.00) (March 24)
  • HSBC: Buy (Raises Target to $32.00) (March 17)
  • Argus Research: Upgraded to Buy (Target $35.00) (March 2)

PFE Shares Fall Tuesday Afternoon

PFE Stock Price Activity: Pfizer shares were down 2.37% at $27.17 at the time of publication on Tuesday, according to Benzinga Pro data.

Image: Shutterstock